Compare Albertsons Companies Inc (ACI) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Albertsons Companies Inc vs Pfizer Inc — how do they compare? Albertsons Companies Inc trades at $12.25 (market cap $5.89B), while Pfizer Inc trades at $26.6 (market cap $154.18B). The key difference: Pfizer Inc is far larger — about 26.2× Albertsons Companies Inc's market cap, and Pfizer Inc pays the higher dividend (6.36%). Which is the better fit depends on your goals.
| ACI | PFE | |
|---|---|---|
Market Cap | $5.89B | $154.18B |
Sector | Consumer Staples | Health |
52-Week High | $19.74 | $28.56 |
52-Week Low | $11.03 | $23.60 |
Enterprise Value | $21.29B | $205.67B |
Dividend Yield | 5.61% | 6.36% |
Volume | — | 29,869,932 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Albertsons (ACI) trades at $12.01, down 0.58% with bearish technical signals despite recent insider buying by the CEO and CFO. The company reported mixed Q2 2026 earnings with a miss on EPS expectations but maintains strong revenue growth trends. Valuation metrics show a high P/E ratio of 75.06 but attractive P/S of 0.08, while profitability remains challenged with net margins at just 0.08%.
The outlook remains cautious with analyst consensus at Buy (35%) but significant legal investigations and margin pressure creating headwinds. The $13.20 price target offers 10% upside potential, though execution risks and competitive grocery market dynamics require careful monitoring for sustained recovery.
Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.
Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Albertsons Companies Inc
Albertsons is the second-largest traditional grocer in America, operating 2,276 stores under 24 banners in 34 states (as of the end of fiscal 2021). Around 75% of stores have pharmacies, while nearly 20% also sell fuel. Albertsons has a significant private-label operation, accounting for around 20% of sales (excluding fuel). While its own brand assortment is mainly manufactured by third parties, Albertsons operates 20 food production plants (as of the end of fiscal 2021). Albertsons is a top-two grocer in two thirds of its major markets (as of early 2022, according to company data), and virtually all of its sales come from the United States.
Read more on ACI →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
